Stocks · News reference
Barclays analyst Andrew Mok maintains Lumexa Imaging Hldgs (NASDAQ:LMRI) with a Overweight and raises the price target from $9 to $13.
Reference Details
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
Keep reading
Lumexa Imaging Holdings (NASDAQ:LMRI) affirms FY2026 Adj EPS guidance from $0.71-$0.77 to $0.71-$0.77 vs $0.62 analyst estimate. Raises FY2026 sales outlook from $1.045 billion-$1.090 billion to $1.045 billion-$1.097
Lumexa Imaging Holdings (NASDAQ:LMRI) reported quarterly earnings of $0.20 per share which beat the analyst consensus estimate of $0.16 by 25 percent. The company reported quarterly sales of $264.200 million which beat
Filed: 2026-06-30 AccNo: 0001193125-26-290788 Size: 260 KB Item 1.01: Entry into a Material Definitive Agreement Item 2.03: Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant Item 9.01: Financial Statements and Exhibits